For a patient with metastatic colon cancer, KRAS WT, when would you consider using EGFR (cetuximab, panitumumab) over VEGF (bevacizumab) antagonists as inital therapy?

Aside from obvious, when patients are contraindicated to bevacizumab due to recent surgery or bleeding, clotting, wound healing problems, I would consider first line if left sided colorectal cancer with negative KRAS, NRAS, BRAF. If you look at the survival benefit with Anti EGFR agents in first lin...